CN116077480A - Application of p-aminobenzoic acid in preparation of medicines for relieving inflammatory bowel disease - Google Patents
Application of p-aminobenzoic acid in preparation of medicines for relieving inflammatory bowel disease Download PDFInfo
- Publication number
- CN116077480A CN116077480A CN202211535241.7A CN202211535241A CN116077480A CN 116077480 A CN116077480 A CN 116077480A CN 202211535241 A CN202211535241 A CN 202211535241A CN 116077480 A CN116077480 A CN 116077480A
- Authority
- CN
- China
- Prior art keywords
- inflammatory bowel
- bowel disease
- aminobenzoic acid
- use according
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 229960004050 aminobenzoic acid Drugs 0.000 title claims description 9
- 229940079593 drug Drugs 0.000 title abstract description 10
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 12
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 2
- 229940063655 aluminum stearate Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 12
- 210000001072 colon Anatomy 0.000 description 5
- 230000007170 pathology Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical group CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229920003045 dextran sodium sulfate Polymers 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- MZKKJVZIFIQOPP-UHFFFAOYSA-M potassium;4-aminobenzoate Chemical compound [K+].NC1=CC=C(C([O-])=O)C=C1 MZKKJVZIFIQOPP-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention belongs to the technical field of biological medicines, and relates to an application of para aminobenzoic acid in preparation of medicines for relieving inflammatory bowel diseases. In the research of para aminobenzoic acid, the PABA has the effect of relieving inflammatory bowel disease, so that the PABA can be used for preparing medicines for relieving inflammatory bowel disease.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and relates to an application of para aminobenzoic acid in preparation of medicines for relieving inflammatory bowel diseases.
Background
The disclosure of this background section is only intended to increase the understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to those of ordinary skill in the art.
Para aminobenzoic acid (4-aminobenzoic acid, PABA) is an intermediate in the synthesis of folic acid by bacteria, plants and fungi, playing a key role in this metabolic pathway. In addition to folate metabolism, PABA is identified as one of the factors required for coenzyme Q precursors and microbial toxicity. PABA is not essential to mammals and cannot be biosynthesized in mammals, but is produced by symbiotic bacteria based on E.coli. In contrast to its importance for certain bacteria, PABA has synergistic antibacterial efficacy against strains including staphylococcus aureus or pseudomonas aeruginosa when combined with several antibiotics. PABA alone has direct antibacterial activity against Listeria, salmonella and E.coli. In addition, it exhibits various antiviral and antioxidant effects. At present, potassium 4-aminobenzoate is mainly used for treating skin diseases such as scleroderma, dermatomyositis and Paeonia's disease.
Disclosure of Invention
In order to solve the problems, the invention aims to provide an application of para-aminobenzoic acid in preparing medicines for relieving inflammatory bowel diseases.
In order to achieve the above purpose, the technical scheme of the invention is as follows:
in one aspect, the use of para-aminobenzoic acid in the manufacture of a medicament for the treatment and/or alleviation of inflammatory bowel disease.
In the research of para aminobenzoic acid, the PABA has the effect of relieving inflammatory bowel disease, so that the PABA can be used for preparing medicines for relieving inflammatory bowel disease.
Further, para-aminobenzoic acid is the only active ingredient in drugs for alleviating inflammatory bowel disease.
Further, the inflammatory bowel disease is ulcerative colitis.
Further, the medicine for relieving inflammatory bowel disease is a pharmaceutical composition, and the pharmaceutical composition consists of p-aminobenzoic acid and pharmaceutical excipients.
The pharmaceutical excipients comprise a pharmaceutical carrier and/or an excipient.
The medicinal carrier comprises alumina, an ion exchanger, lecithin or aluminum stearate and the like.
The excipient of the present invention includes disintegrating agent, binding agent, preservative, filling agent, etc.
The disintegrating agent is sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, potato starch and the like.
The binder is water, ethanol, syrup, gelatin and the like.
The preservative is chlorobutanol, sorbitol and the like.
The filler is lactose, microcrystalline cellulose, dextrin, and the like.
Further, the formulation of the medicine for relieving inflammatory bowel disease is granules, tablets, pills, capsules, powder, solutions, aerosols, suspensions, dripping pills, emulsions and the like.
The content of the p-aminobenzoic acid in the dosage form is 0.1-30 percent (mass percent).
Further, the dosage of the medicine for relieving inflammatory bowel disease is 90-110 mg/kg based on the para aminobenzoic acid.
The beneficial effects of the invention are as follows:
experiments on mice with ulcerative colitis induced by DSS show that compared with a control group, mice in a treatment group fed with p-aminobenzoic acid have less weight drop, obvious increase of colon and less inflammatory cell infiltration, and the combination of pathological score statistical results shows that the p-aminobenzoic acid can reduce the severity of ulcerative colitis, relieve inflammatory bowel diseases and has better treatment effect in an experimental ulcerative colitis model of mice.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention.
Fig. 1 is a representation diagram of sodium p-aminobenzoate-relieving dextran sulfate (DSS) -induced ulcerative colitis in an embodiment of the invention, a is an experimental scheme, B is a mouse weight change curve, C is a colon length comparison picture, D is a HE staining picture, and E is a pathology score statistics result diagram.
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
In order to enable those skilled in the art to more clearly understand the technical scheme of the present invention, the technical scheme of the present invention will be described in detail with reference to specific embodiments.
Examples
Experimental materials:
experimental animals: c57BL/6J, male, 6 week old, purchased from Jiangsu Jiuyaokang Biotech Co. Mice were kept in SPF-class zoo at Shandong university college of pharmacy in an SPF-class environment, conforming to Shandong university animal keeping and management regulations. All animal experiments and procedures were performed strictly in accordance with the university of Shandong laboratory animal regulations.
Experimental reagent:
dextran sodium sulfate (Dextran Sulfate Sodium Salt Colitis Grade, DSS): available from MP Biomedicals (1601110).
4% paraformaldehyde universal tissue fixative: 4% paraformaldehyde, 1.9mM sodium dihydrogen phosphate dihydrate, 8.1mM disodium hydrogen phosphate dodecahydrate, available from He-Felidae technologies Co., ltd (BL 539A).
The experimental method comprises the following steps:
establishment and treatment of experimental ulcerative colitis model in mice:
(1) After one week of C57BL/6J 8, 6 week old, male, SPF grade, 3% DSS was given water along with PABA treatment.
(2) PABA was formulated and mice were gavaged at a dose of 100mg/kg, and the control group was gavaged with an equal volume of sterile water once daily.
(3) Each group of mice was weighed daily, sacrificed on day 6, colon was collected for assessment, statistical length differences, HE staining followed by pathology scoring.
(4) All mouse weights examined were statistically analyzed using Graph Pad Prism 9 software and weight change curves were plotted.
Experimental results:
body weight change curve and pathology:
to investigate the therapeutic effect of PABA in ulcerative colitis, 6 week old male C57BL/6J mice were selected, and experimental ulcerative colitis models were established for 3% DSS and randomly divided into two groups, control and PABA treatment groups, respectively. Treatment group mice were perfused with PABA at a dose of 100mg/kg, control group was perfused with an equal volume of sterile water, and the mice were perfused once daily starting with Day 0 while measuring their body weights daily (FIG. 1A). Fig. 1B is a graph showing the change in body weight of mice, and it can be seen from the graph that the body weight of the treatment group is reduced less than that of the Control group. From the statistics of colon length, the pala-treated colon was significantly longer than the control (fig. 1C). HE staining results showed that the intestinal epithelium of the PABA treated group was more complete, less inflammatory cell infiltration and less submucosal edema than the control group (fig. 1D). Analysis of pathology score statistics showed that PABA treatment significantly reduced ulcerative colitis in mice compared to the control group (figure 1E). These results indicate that PABA can reduce the severity of ulcerative colitis, alleviate inflammatory bowel disease, and has better therapeutic effect in experimental ulcerative colitis models in mice.
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. Use of para aminobenzoic acid in the preparation of a medicament for the treatment and/or alleviation of inflammatory bowel disease.
2. Use according to claim 1, wherein p-aminobenzoic acid is the only active ingredient in the medicament for reducing inflammatory bowel disease.
3. The use of claim 1, wherein the inflammatory bowel disease is ulcerative colitis.
4. The use according to claim 1, wherein the medicament for alleviating inflammatory bowel disease is a pharmaceutical composition consisting of p-aminobenzoic acid and a pharmaceutical excipient.
5. The use according to claim 4, wherein the pharmaceutical excipients comprise pharmaceutically acceptable carriers and/or excipients.
6. The use according to claim 4 wherein the pharmaceutically acceptable carrier comprises alumina, ion exchanger, lecithin or aluminum stearate.
7. The use according to claim 4, wherein the excipient comprises a disintegrant, a binder, a preservative and/or a filler.
8. The use according to claim 1, wherein the agent for reducing inflammatory bowel disease is in the form of granules, tablets, pills, capsules, powders, solutions, aerosols, suspensions, drops or emulsions.
9. The use according to claim 8, wherein the content of p-aminobenzoic acid in the dosage form is 0.1-30% by mass.
10. The use according to claim 1, wherein the amount of the agent for alleviating inflammatory bowel disease administered is from 90 to 110mg/kg calculated as para-aminobenzoic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211535241.7A CN116077480A (en) | 2022-12-02 | 2022-12-02 | Application of p-aminobenzoic acid in preparation of medicines for relieving inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211535241.7A CN116077480A (en) | 2022-12-02 | 2022-12-02 | Application of p-aminobenzoic acid in preparation of medicines for relieving inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116077480A true CN116077480A (en) | 2023-05-09 |
Family
ID=86200031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211535241.7A Pending CN116077480A (en) | 2022-12-02 | 2022-12-02 | Application of p-aminobenzoic acid in preparation of medicines for relieving inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116077480A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050220705A1 (en) * | 2004-01-21 | 2005-10-06 | New York University | Methods for treating non-melanoma cancers with PABA |
| CN109620820A (en) * | 2019-01-30 | 2019-04-16 | 桂林医学院 | Application of the P-hydroxybenzoic acid in preparation treatment inflammatory bowel medicine |
-
2022
- 2022-12-02 CN CN202211535241.7A patent/CN116077480A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050220705A1 (en) * | 2004-01-21 | 2005-10-06 | New York University | Methods for treating non-melanoma cancers with PABA |
| CN109620820A (en) * | 2019-01-30 | 2019-04-16 | 桂林医学院 | Application of the P-hydroxybenzoic acid in preparation treatment inflammatory bowel medicine |
Non-Patent Citations (2)
| Title |
|---|
| AKIRA YAMAMOTO: "Absorption and Metabolic Characteristics of p-Aminobenzoic Acid and Its Isomer, m-Aminobenzoic Acid, from the Rat Small Intestine", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 80, no. 11, 30 November 1991 (1991-11-30), pages 1067 - 1071 * |
| ARTHUR L.: "Biotransformation of para-aminobenzoic acid and salicylic acid by PMN", ARCHIVES OF GENERAL INTERNAL MEDICINE., vol. 14, no. 1, 31 January 1993 (1993-01-31), pages 27 - 35 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101084944B (en) | Composition for prophylaxis or treatment of urinary system infection | |
| US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
| JP6429131B2 (en) | External composition for skin containing salt and sugar as active ingredients for the prevention and treatment of vaginosis and use thereof | |
| US20170258861A1 (en) | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | |
| US20230293476A1 (en) | Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of pain | |
| JP2017186381A (en) | Method and formulation for treating sialic acid deficiency | |
| Young et al. | Naftidrofuryl treatment for rest cramp | |
| CN116077480A (en) | Application of p-aminobenzoic acid in preparation of medicines for relieving inflammatory bowel disease | |
| US20070264370A1 (en) | Composition and methods for the treatment of joint pain using Angelica gigas Nakai extract and powder as combined with Glucosamine Sulfate, or Chondroitin Sulfate and HCL, or MSM, or aspirin, or Celedrin, and as combinations thereof in powder, pill, capsule, spray, liquid, and gelcap form | |
| US8158159B2 (en) | Pharmaceutical formulation for treating tinea of feet and hands and preparation thereof | |
| EP1374903B1 (en) | Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases | |
| EP2329819B1 (en) | Pharmaceutical composition for use in treating sexually transmitted infections | |
| EP3496714A1 (en) | Drug compositions | |
| US20220387379A1 (en) | Modified herbal compositions for neuromodulation | |
| Mosalaei et al. | Effect of oral zinc sulphate in prevention of radiation induced oropharyngeal mucositis during and after radiotherapy in patients with head and neck cancers | |
| CN114588141A (en) | Medicine for treating psoriasis | |
| EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN1136002C (en) | Chinese-medical buccal lozenge and its preparing process | |
| US4039684A (en) | Method for treatment of canine seborrhea | |
| CN100486597C (en) | A pharmaceutical composition made from Chinese traditional medicine for treating snuffle, headache and preparation method thereof | |
| CN114366732B (en) | Application of tiamulin in preparation of medicine for treating psoriasis | |
| CN117530951B (en) | Composition for treating cold and preparation method and application thereof | |
| Abengowe | Comparative trial of co-trimoxazole and tetracycline in the treatment of lower respiratory tract infection | |
| Banerjee | Treatment Trial | |
| CN114515289A (en) | Compound preparation containing levofloxacin and cimetidine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |